Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...
Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...
5don MSN
Reduced synapse protein SNAP 25 found in patients with major depressive disorder and schizophrenia
People with major depressive disorder or schizophrenia have been found to have lower levels of the synaptic protein "SNAP-25" ...
MedPage Today on MSN
FDA Broadens Caplyta Approval to Include Major Depression
The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive ...
The expanded indication for the oral atypical antipsychotic now includes adjunctive use with antidepressants in adults with major depressive disorder.
Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved ...
Share on Pinterest Emerging evidence suggests that a ketogenic diet could help support mental health. Alexander Spatari/Getty Images A new pilot study reports that young adults experienced a 70% ...
For many people with major depressive disorder (MDD), the first or second antidepressant doesn't cut it. Maybe your sleep gets better. Maybe the darkest thoughts ease up. But you still slog through ...
The novel serotonin norepinephrine reuptake inhibitor (SNRI) ammoxetine may effectively treat major depressive disorder (MDD) while avoiding some side effects common to other antidepressants, new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback